Marshall Wace
SANA icon

Marshall Wace’s Sana Biotechnology SANA Stock Holding History

Marshall Wace’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Buy
664,457
+575,669
+648% +$2.27M ﹤0.01% 1810
2025
Q4 		$361K Buy
+88,788
New +$398K ﹤0.01% 2382
2025
Q2 		– Sell
-211,227
Closed -$355K – 3104
2025
Q1 		$355K Buy
211,227
+189,905
+891% +$531K ﹤0.01% 2202
2024
Q4 		$34.8K Sell
21,322
-372,359
-95% -$1.11M ﹤0.01% 2501
2024
Q3 		$1.64M Buy
393,681
+205,968
+110% +$1.08M ﹤0.01% 1442
2024
Q2 		$1.02M Sell
187,713
-682,272
-78% -$5.44M ﹤0.01% 1676
2024
Q1 		$8.7M Buy
+869,985
New +$6.52M 0.01% 792
2023
Q4 		– Sell
-79,069
Closed -$306K – 2560
2023
Q3 		$306K Sell
79,069
-8,560
-10% -$46K ﹤0.01% 1878
2023
Q2 		$522K Buy
+87,629
New +$505K ﹤0.01% 1963
2022
Q4 		– Sell
-29,180
Closed -$175K – 3356
2022
Q3 		$175K Buy
+29,180
New +$211K ﹤0.01% 3113

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Marshall Wace's SANA Position: Q1 2026 in Review

Marshall Wace increased its Sana Biotechnology (SANA) stake by 648% in Q1 2026, buying an estimated $2.27M and bringing the position to 664,457 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1810.

Marshall Wace first reported a position in SANA in Q3 2022 and has held it in 10 quarters since. The position peaked at $8.7M in Q1 2024. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Marshall Wace held 664,457 shares of Sana Biotechnology worth $1.91M as of Q1 2026.
  • Marshall Wace bought 575,669 Sana Biotechnology shares in Q1 2026, an estimated $2.27M.
  • Sana Biotechnology made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1810 holding.
  • Marshall Wace first reported a position in Sana Biotechnology in Q3 2022 and has held it in 10 quarters since.
  • Marshall Wace's Sana Biotechnology position peaked at $8.7M in Q1 2024.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.